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Abstract: 
Aims: Endothelial-derived epoxyeicosatrienoic acids may regulate vascular 
tone and are metabolised by soluble epoxide hydrolase enzymes (sEH). 
GSK2256294 is a potent and selective sEH inhibitor that was tested in two 
Phase I studies.  
Methods: Single escalating doses of GSK2256294 2-20 mg or placebo were 
administered in a randomized crossover design to healthy male subjects or 
obese smokers; once daily doses of 6 or 18 mg or placebo were 
administered for 14 days to obese smokers.  Data were collected on safety, 
pharmacokinetics, sEH enzyme inhibition and blood biomarkers. Single 
doses of GSK2256294 10 mg were also administered to healthy younger 
males or healthy elderly males and females with and without food.  Data 
on safety, pharmacokinetics and biliary metabolites were collected.  
Results: GSK2256294 was well-tolerated with no serious adverse events 
(AEs) attributable to the drug. The most frequent AEs were headache and 
contact dermatitis.  Plasma concentrations of GSK2256294 increased with 
single doses, with a half-life averaging 25-43 hours. There was no 
significant effect of age, food or gender on pharmacokinetic parameters. 
Inhibition of sEH enzyme activity was dose-dependent, from an average of 
41.9% on 2 mg (95% confidence interval [CI] -51.8, 77.7) to 99.8% on 20 
mg (95% CI 99.3, 100.0) and sustained for up to 24 hours.  There were no 
significant changes in serum VEGF or plasma fibrinogen.  
Conclusions: GSK2256294 was well-tolerated and demonstrated sustained 
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inhibition of sEH enzyme activity.  These data support further investigation 
in patients with endothelial dysfunction or abnormal tissue repair, such as 
diabetes, wound healing or COPD. 
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Abstract 22 
Aims: Endothelial-derived epoxyeicosatrienoic acids may regulate vascular tone and 23 
are metabolised by soluble epoxide hydrolase enzymes (sEH). GSK2256294 is a 24 
potent and selective sEH inhibitor that was tested in two Phase I studies.  25 
Methods: Single escalating doses of GSK2256294 2-20 mg or placebo were 26 
administered in a randomized crossover design to healthy male subjects or obese 27 
smokers; once daily doses of 6 or 18 mg or placebo were administered for 14 days to 28 
obese smokers.  Data were collected on safety, pharmacokinetics, sEH enzyme 29 
inhibition and blood biomarkers. Single doses of GSK2256294 10 mg were also 30 
administered to healthy younger males or healthy elderly males and females with 31 
and without food.  Data on safety, pharmacokinetics and biliary metabolites were 32 
collected.  33 
Results: GSK2256294 was well-tolerated with no serious adverse events (AEs) 34 
attributable to the drug. The most frequent AEs were headache and contact 35 
dermatitis.  Plasma concentrations of GSK2256294 increased with single doses, with 36 
a half-life averaging 25-43 hours. There was no significant effect of age, food or 37 
gender on pharmacokinetic parameters. Inhibition of sEH enzyme activity was dose-38 
dependent, from an average of 41.9% on 2 mg (95% confidence interval [CI] -51.8, 39 
77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 hours.  40 
There were no significant changes in serum VEGF or plasma fibrinogen.  41 
Conclusions: GSK2256294 was well-tolerated and demonstrated sustained 42 
inhibition of sEH enzyme activity.  These data support further investigation in patients 43 
with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound 44 
healing or COPD.   45 
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What is known about this subject? 47 
• Soluble epoxide hydrolase (sEH) is a critical enzyme in the metabolism of 48 
epoxyeicosatrienoic acids (EETs). 49 
 50 
• EETs released from the endothelium exhibit anti-inflammatory effects, 51 
regulate vascular tone and may have a cytoprotective role 52 
 53 
• GSK2256294 is a potent and selective, orally-available sEH inhibitor 54 
 55 
What this study adds  56 
GSK2256294 is a well-tolerated and highly effective oral sEH inhibitor irrespective of 57 
age, gender or food administration.   58 
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Introduction 59 
Epoxyeicosatrienoic acids (EETs) are one of many vasoactive factors released by 60 
the vascular endothelium, including nitric oxide (NO), prostacyclin, and endothelium 61 
derived hyperpolarizing factors. EETs are formed by the oxidation of arachidonic acid 62 
by cytochrome P450 enzymes. Soluble epoxide hydrolase (sEH, an EPHX2 gene 63 
product) is a critical enzyme in the metabolism of EETs to their corresponding much 64 
less active or less available dihydroxyeicosatrienoic acids (DHETs) [1,2].  In addition, 65 
EPHX2 contains a phosphatase domain of unknown function.  EETs have 66 
demonstrated a wide range of activities including protection of endothelial cell 67 
survival and function in both coronary and pulmonary derived cells, as well as anti-68 
inflammatory and pro-resolving functions and protection of organs from damage [3–69 
5]. The mechanism of action of EETs is complex, and may include changes in 70 
potassium channel open states, as well as engagement of as yet unidentified 71 
receptors or action through peroxisome proliferator-activated receptors [3]. 72 
Preclinical data with sEH inhibitors provide evidence for a number of potentially 73 
beneficial cardioprotective effects [6–10].  Exogenous EETs and sEH inhibitors are 74 
also efficacious in a wide variety of animal models of pulmonary disease such as 75 
smoke-induced airway inflammation and airspace enlargement, allergen-induced 76 
airway inflammation, bleomycin-induced pulmonary fibrosis and toxin-induced lung 77 
injury [11–16].  High levels of sEH activity inversely correlate with low concentrations 78 
of the pro-resolving lipoxin A4 in sputum supernatants of patients with severe asthma 79 
[17].  It is proposed that the inhibition of sEH will increase the cellular concentration 80 
of EETs and thus increase their positive cellular effects.   81 
Clinical studies with sEH inhibitors are limited.  The selective sEH inhibitor AR9281 82 
(Arete Pharmaceuticals) was shown to improve endothelial function in animal models 83 
[18] and demonstrated inhibition of enzyme activity and a modest decrease in 84 
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dihydroxy lipids in a clinical study in healthy subjects [19]. A Phase 2 trial to assess 85 
effects on blood pressure and glucose metabolism in patients with moderate 86 
hypertension and impaired glucose tolerance was terminated (NCT00847899). 87 
GSK2256294 is a potent, tight-binding but reversible inhibitor of sEH.  It is specific for 88 
the hydrolase domain of EPHX2 and is inactive against the phosphatase domain and 89 
has been shown to attenuate cigarette smoke-induced lung inflammation in animal 90 
models [20]. We report data from two clinical trials designed to test the safety, 91 
pharmacokinetics, and pharmacodynamics of GSK2256294 in healthy subjects.  92 
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Methods 93 
Clinical Study design  94 
Study 1, First-time-in-human (FTIH, GSK protocol SEH114068, ClinicalTrials.gov 95 
identifier NCT01762774). The FTIH study was a single-center, randomized, double-96 
blind, placebo-controlled design comprising four cohorts.  Study 1 recruited healthy 97 
male non-smokers between 18-65 years of age with body mass index (BMI) 19-98 
25kg/m2 for Cohort 1, and moderately overweight smokers (defined as ≥10 99 
cigarettes/day for at least 1 year prior to the screening visit) with BMI 26 – 35kg/m2 100 
for Cohorts 2-4. Subjects with abnormal liver function, who were on statins, or who 101 
had hypertension or other significant cardiac, pulmonary, metabolic, renal, or 102 
gastrointestinal conditions, were excluded.  103 
Single escalating doses of GSK2256294 (2, 6, 10, 12, and 20mg) or placebo were 104 
administered in a randomised crossover design to Cohorts 1 and 2. Single dosing 105 
subjects followed a 4-period dosing schedule with placebo insertion, such that all 106 
subjects received placebo and three doses of the active drug randomly over the 107 
course of the study. Subjects were assigned to the treatment regimens in 108 
accordance with a randomisation schedule that included 4 sequences with 3 subjects 109 
assigned to each sequence. 110 
The emerging pharmacokinetic (PK) and pharmacodynamic (PD) data from Cohorts 111 
1 and 2 were modelled with a population exposure-response analysis approach to 112 
select appropriate doses for repeat dosing cohorts. Two cohorts of overweight 113 
smokers were subsequently recruited for repeat dosing, with one cohort randomised 114 
to receive either 6mg or placebo (Cohort 3), and another 18 mg or placebo (Cohort 115 
4). Fifteen subjects were planned for each cohort with 12 randomised to the active 116 
arm and 3 to placebo.  Data were collected on safety, PK, sEH enzyme inhibition and 117 
blood biomarkers. An experimental medicine study in Cohorts 3 and 4, to provide 118 
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early proof of mechanism of the potential biological effects of sEH inhibition on 119 
endothelial function using measurements of forearm blood flow, was also included, 120 
but reported separately [21]. The trial received favourable ethical opinion from the 121 
London Bloomsbury Ethics Committee (12/LO/1832) as well as regulatory approval 122 
by the MHRA.   123 
Study 2, Food effect (GSK protocol SEH117023, ClinicalTrials.gov identifier 124 
NCT02006537). The food effect study was open label and performed at a single 125 
center.  Subjects included healthy males between 18-45 years of age recruited for 126 
Cohort 1, and healthy male and females (of non-child bearing potential) aged ≥60 127 
years of age recruited for Cohort 2. 128 
Subjects in Cohort 1 received a single dose of GSK2256294 10mg, and underwent 129 
non-invasive bile sampling with the Entero-Test® device, as previously described 130 
[22].  Subjects in Cohort 2 were randomized to receive two single doses of 131 
GSK2256294 10 mg in both the fed and fasted state. This trial was reviewed and 132 
approved by the Aspire Institutional Review Board (Santee, CA, USA). 133 
Both studies complied with the Declaration of Helsinki 2008 and ICH Good Clinical 134 
Practice guidelines, and full written informed consent was obtained from all 135 
participants before the performance of any study-specific procedures. A complete list 136 
of inclusion and exclusion criteria is available on clinicaltrials.gov. 137 
Safety 138 
Safety assessments were monitored using adverse event (AE) reporting, clinical 139 
laboratory tests, vital signs, ECGs, and physical examinations. In the single dose 140 
escalation phase of Study 1, 25-hour continuous Holter and electrocardiographic 141 
monitoring were performed from 1hr pre-dose to 24 hours post-dose.  142 
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The addition of EETs and/or inhibition of sEH have been linked in preclinical studies 143 
to two important activities that pose potential clinical risks.  The first set of studies 144 
concerns the role of EETs and sEH in VEGF signaling and expression [23,24]; for 145 
this reason, we measured VEGF concentrations in the repeat dose cohorts of Study 146 
1 (described below).  The second set of studies concerns control of acute pulmonary 147 
vasoconstriction and pulmonary hypertension.  Mice in which the sEH gene has been 148 
deleted develop pulmonary hypertension in response to chronic hypoxia, but sEH 149 
inhibition in wild-type mice does not recapitulate the knockout [25].  At this time, a 150 
role of the EPHX2 gene in development of pulmonary hypertension is focused on the 151 
phosphatase domain, which is unaffected by GSK2256294 [20]; nevertheless, we 152 
measured pulmonary artery pressure using transthoracic echocardiography in the 153 
repeat dose cohorts of Study 1.  154 
Measurement of GSK2256294 155 
GSK2256294 was extracted from 50 µL of human plasma by protein precipitation 156 
using acetonitrile containing an isotopically labelled internal standard ([2H3
13C]-157 
GSK2256294) and extracts were analysed for GSK2256294 by HPLC-MS/MS using 158 
a TurboIonSpray™ interface and multiple reaction monitoring. The assay was 159 
validated over the range 0.6 to 250 ng/mL of GSK2256294, with calibration 160 
correlation coefficients of >0.996, obtained using 1/(x2) weig ted linear regression. 161 
The assay precision (%CV) was ≤12.9% for within-run and ≤4.7% between-runs, with 162 
an accuracy (%bias) between -9.5%≤ bias ≤14.5%. 163 
Soluble Epoxide Hydrolase Activity Assay 164 
Blood samples were collected from subjects in Cohorts 1-4 (Study 1), immediately 165 
mixed by inversion in NaF/Potassium oxalate containing tubes and stored at 2-8°C 166 
for up to 12 hours (if not processed immediately). Whole blood samples were 167 
assessed for both sEH activity and non-sEH mediated EET hydrolysis, by pre-168 
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incubating for 20 minutes at room temperature with either 25 mM HEPES/10 µM 169 
CHAPS buffer (pH 7-7.6) either alone or with addition of a known potent sEH inhibitor 170 
(final concentration 10uM GSK2188931), respectively. The reactions were initiated 171 
by the addition of 14,15-EET-deuterated (d11) substrate in HEPES/CHAPS buffer 172 
(0.45 µM final concentration) and incubated for 30 minutes at room temperature. The 173 
enzymatic reaction was terminated by the addition of zinc sulfate (3.3 mM final 174 
concentration) and subsequently diluted with an equal volume of distilled water 175 
(~300uL) prior to storage at ca. -70°C. Samples were analysed for the conversion of 176 
14,15-EET-d11 to 14,15-DHET-d11 by LC/MS/MS, using an assay that was validated 177 
over the range 0.5 to 500 ng/mL for 14,15-EET-d11 and 0.1 to 100 ng/mL for 14,15-178 
DHET-d11, with calibration correlation coefficients obtained using 1/(x2) weighted 179 
linear regression of >0.996 and 0.997, respectively. The assay precision (%CV) was 180 
≤17.5% (14,15-EET-d11) and ≤13.3% (14,15-DHET-d11) for within-run and ≤4.6% 181 
(14,15-EET-d11) and ≤13.7% (14,15-DHET-d11) between-runs, with an accuracy 182 
(%bias) between -9.2% ≤ bias ≤5.7% (14, 15 EET) and -5.5% ≤ bias ≤22.9% (14, 15 183 
DHET).  The sEH activity was evaluated by the formation of 14,15-DHET-d11, 184 
corrected for non-sEH mediated hydrolysis and subsequently the % inhibition of sEH 185 
activity following GSK2256294 dose escalation was defined. 186 
Blood biomarkers 187 
VEGF was measured using a validated ELISA (performed by Quest Diagnostics, 188 
Valencia, CA). Plasma fibrinogen was measured using the modified Clauss method.  189 
Detailed methods for the analysis of Leukotoxin/Leukotoxin-diol (LT/LTD) assays are 190 
included in the Supplemental material [26].  191 
Analysis and Statistical methods 192 
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These studies focused primarily on the safety, tolerability, and pharmacokinetics (PK) 193 
of GSK2256294, and no formal hypotheses around the pharmacodynamic 194 
assessments were tested. 195 
Plasma concentration-time data were analysed by non-compartmental methods with 196 
WinNonlin 6.3 and calculations were based on the actual sampling times recorded 197 
during the study.  Actual elapsed times from dosing were used to estimate all 198 
individual plasma PK parameters for evaluable subjects. Based on available data, 199 
various PK parameters were estimated following GSK2256294 dose administration in 200 
single dose and repeat dose, including maximum observed plasma concentration 201 
(Cmax), time to Cmax (tmax), the apparent terminal elimination half-life (t1/2), and 202 
the area under the plasma concentration-time curve (AUC). Descriptive statistics (n, 203 
arithmetic mean, standard deviation, 90% CI, minimum, median and maximum) were 204 
calculated for all PK parameters by treatment. Dose proportionality was assessed by 205 
using Power model and Analysis of Variance.  206 
A preliminary interim analysis of the systemic concentrations of GSK2256294 207 
(exposure) and the sEH enzyme inhibition (response) data was conducted to select a 208 
starting dose for the repeat dose arm using a population modeling and simulation 209 
approach. 210 
 211 
  212 
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Results 213 
Safety 214 
Fifty-six male subjects aged 18-65 years inclusive were recruited to take part in 215 
Study 1. Fourteen healthy male non-smokers were recruited into cohort 1, and 42 216 
moderately overweight smokers were recruited into cohorts 2 - 4. Forty-eight 217 
subjects completed the study as planned. Detailed subject disposition is shown in 218 
Figure 1.  In study 2, 8 subjects were randomized into Cohort 1 and 18 subjects were 219 
randomized into Cohort 2.  All subjects completed the study. Demographics for both 220 
studies are shown in Table S1 of the online supplement.  221 
Overall, GSK2256294 was well-tolerated with no serious adverse reactions attributed 222 
to the drug. One serious adverse event of nephrolithiasis occurred in a subject who 223 
received a single dose of 2 mg in Study 1; this subject had a previous history of 224 
nephrolithiasis and the event was not considered to be drug-related, although the 225 
subject was withdrawn from the study. One additional subject was withdrawn after a 226 
vasovagal episode while a blood sample was being obtained, which was not felt to 227 
be drug-related. No subjects were withdrawn for adverse events in the repeat dose 228 
cohorts. 229 
The most frequent adverse events in study 1 were headache and contact dermatitis 230 
in the healthy subjects (Cohort 1), and headache and nasopharyngitis in the obese 231 
smokers (cohorts 2-4)(Supplemental Tables S2-S4). The occurrence of AEs was 232 
similar between the active and placebo groups, with the exception of contact 233 
dermatitis at the site of ECG electrode placement, which occurred in 9 healthy 234 
subjects receiving the active drug, and none in the placebo group. The majority of 235 
AEs were mild-moderate in severity.  In the single dose cohorts, five subjects were 236 
noted to have a transient elevation of creatinine at the 12 hour time point after dosing 237 
(1 on placebo, 2 each on GSK2256294 2mg or 6 mg).  Contemporaneous Cystatin C 238 
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concentrations in these subjects were normal (data not shown) and creatinine 239 
concentrations were within the normal range at the 24 hour time point.  No changes 240 
in creatinine were noted in the repeat dose cohorts.  The subject with nephrolithiasis 241 
was noted to have increased hepatic transaminases at the time of his hospitalization.  242 
One additional subject had a transient increase in alanine aminotransferase noted 243 
after a single dose of 10 mg GSK2256294; no clinically significant changes in 244 
transaminases were seen in the repeat dose cohorts. Finally, there were no changes 245 
in the pulmonary artery pressures of subjects who received 14 days repeat dosing of 246 
GSK2256294 in Study 1. 247 
There were 3 AEs in study 2 and none was reported in more than one person (Table 248 
S5). No clinically significant differences in ECG or vital signs were noted in either 249 
study.   250 
Pharmacokinetics and Metabolism 251 
GSK256294 was well absorbed with maximum systemic concentrations achieved 252 
around 1-2 hours and with a dose proportional increase in systemic exposure from 6 253 
mg to 20 mg. The observed half-life was 20-30 hours (Figure 2A).  The exposure and 254 
t½ were slightly higher in obese smokers as compared to healthy volunteers (Table 255 
1). With once daily repeat dosing, steady state was achieved within 6-8 days and 256 
resulted in approximately 2 fold accumulation (Figure 2B).   257 
The preliminary exposure data and enzyme inhibition data from the single dose 258 
cohorts in FTIH were utilized to characterize the sEH enzyme inhibition and 259 
determine an approximate clinical dose for the repeat dose cohorts.  An indirect 260 
response model was built to characterize the sustained enzyme inhibition following 261 
single dose administration. A population kinetic-pharmacodynamic model (KPD) 262 
model adequately characterized the observed sEH enzyme inhibition at different 263 
dose levels. The doses rather than systemic drug concentrations provided a better fit 264 
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of the observed data and this the KPD approach was used [27]. Simulations were 265 
performed with the KPD model to predict the probability of 90% or higher level of 266 
enzyme inhibition after 2 weeks of once daily dosing at different dose levels. The 6 267 
mg dose presented a very high probability of achieving >90% sEH enzyme inhibition 268 
at once daily dosing for 2 weeks.  Assuming a less than 2 fold accumulation, the 18 269 
mg dose was then selected to help characterize the safety and tolerability of a high 270 
dose of GSK2256294, while maintaining exposures within the stopping criteria based 271 
on animal safety studies. 272 
Data from Study 2 demonstrated no impact on systemic exposure of GSK2256294 273 
due to age or gender. There was an approximately 22% increase 1.22 (90% CI 1.10, 274 
1.34) in AUC when GSK2256294 was administered with FDA recommended meal as 275 
compared to fasted state with no change in the Cmax. This increase in exposure 276 
when GSK2256294 is administered with food is clinically insignificant. 277 
 278 
In Study 2, GSK2256294 and five metabolites were detected in the pooled human 279 
duodenal bile samples by mass spectroscopy.  Unchanged parent was the major 280 
drug-related component, with metabolites being formed by oxidation with or without 281 
subsequent glucuronidation (data not shown). 282 
 283 
sEH Enzyme inhibition  284 
.  Following single doses of GSK2256294, there was a dose-dependent inhibition 285 
from an average of 41.9% on 2 mg (95% CI -51.8, 77.7) to an average of 99.8% on 286 
20 mg (95% CI 99.3, 100.0)(Figure 3A).  The duration of inhibition was sustained for 287 
up to 24 hours. Near maximal inhibition of sEH enzyme activity (98-99%) was 288 
observed for both 6mg and 18 mg following 14 days repeated dosing (Figure 3B). 289 
Repeat dose enzyme inhibition at 6 mg/day and 18 mg/day (Cohorts 3 and 4, 290 
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respectively) was consistent with the single dose inhibition at 6 hr (98-99 %) at both 291 
doses, and this was maintained at 24h after repeat dosing. 292 
A large number of the endogenous LT levels were non-quantifiable, as they were 293 
below the limit of LC/MS/MS assay detection (LLQs of 250 pg/mL and 50 pg/mL for 294 
LT and LTD, respectively). In addition, there were no meaningful changes in the 295 
LT/LTD ratio between any of the three treatment arms compared to baseline at any 296 
time point (data not shown).  297 
Blood biomarkers 298 
In the repeat dosing subjects in Study 1, there were no significant changes in VEGF 299 
concentrations from baseline to day 15. The fold change from baseline in the placebo 300 
group was 1.06 (95% CI: 0.73, 1.55), and 1.15 (95% CI: 0.85, 1.56), in the 6mg 301 
group.  There was a trend for a decrease in VEGF in subjects receiving 18mg of 302 
GSK2256294 (ratio to baseline 0.77 (95% CI: 0.56, 1.05)). 303 
Adjusted mean values of plasma fibrinogen were within the normal range and were 304 
similar across all groups.  The average difference at day 15 compared with placebo 305 
was negligible.  The fold change from baseline in subjects who received 6mg 306 
GSK2256294 was 1.06 (95% CI: 0.82, 1.37), and 1.04 (95% CI: 0.81, 1.34) in those 307 
who received 18mg GSK2256294.  308 
  309 
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Discussion 310 
We report the first studies to assess the safety, pharmacokinetics and 311 
pharmacodynamic effects of the sEH inhibitor GSK2256294, in healthy subjects and 312 
otherwise healthy overweight smokers.  Overweight smokers represent a population 313 
with endothelial dysfunction manifested by reduced NO-mediated vasodilatation and 314 
impaired fibrinolytic pathways; in this situation, up-regulation of EETs would be 315 
expected to play a compensatory role.  Preclinical studies of sEH inhibition in models 316 
of metabolic syndrome support obesity as a factor regulating this pathway [8,28]. 317 
Finally, smoking has a synergistic effect with sEH polymorphisms coding for 318 
enhanced sEH enzyme [29], though subjects were not genotyped in this study. 319 
GSK2256294 was rapidly absorbed and demonstrated an approximately dose 320 
proportional increase in exposure from 6 mg to 20 mg dose with a half life consistent 321 
with once daily dosing.  The majority of GSK2256294 was cleared within 72 hrs of 322 
dosing, yet very low concentrations of parent compound were detectable in the 323 
plasma for up to 3 weeks.  While the mechanism for this is unknown, one potential 324 
explanation may be that a small amount of GSK2256294 is distributed to a deep 325 
compartment and was then eliminated slowly. 326 
GSK2256294 was well tolerated following both single and repeat dosing, and the 327 
majority of adverse events were classified as mild to moderate. Transient elevations 328 
of creatinine were noted in the single dose cohorts of the FTIH study that were 329 
considered possibly drug-related, and occurred primarily in subjects receiving 330 
GSK2256294. These events were only noted at a single time point, occurred soon 331 
after a meal and only at 2 and 6 mg but not higher doses, and did not re-occur with 332 
subsequent dosing, nor were they associated with elevations in serum cystatin C or 333 
urinalysis abnormalities. No changes in creatinine were observed in the repeat dose 334 
cohorts. The etiology of these transient changes is unknown. One possibility which 335 
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may explain why this was only seen at lower doses, and not in repeat dosing, is the 336 
fact that the 12 hour blood sampling point was only done in Cohorts 1 and 2, i.e. 337 
immediately after the evening meal, and that the changes in creatinine were related 338 
to dietary intake (a heavy protein meal eaten immediately prior to sampling) as 339 
previously reported in the literature [30], although a formal dietary chart was not kept 340 
for the trial. 341 
In pre-clinical models, EETs increase the proliferation and survival of endothelial 342 
cells [31] as well as induce angiogenesis [32,33].  The critical role for EETs in organ 343 
regeneration and tissue repair may be dependent on this effect [34].  Using the same 344 
experimental model, investigators also demonstrated that transgenic overexpression 345 
of EETs or inhibition of sEH promoted tumor growth and metastasis [35]. In contrast, 346 
dual inhibition of cyclo-oxygenase 2 and soluble epoxide hydrolase has 347 
demonstrated synergistic anti-angiogenic and anti-cancer activity [36].  The 348 
relevance of these models to humans is unknown, but suggests that the regulation of 349 
sEH activity and tissue EETs in tumor growth is complex.  In the FTIH study, serum 350 
VEGF concentrations were not increased following 2 weeks of dosing with 351 
GSK2256294, and actually trended lower in subjects who received the higher dose.  352 
One might speculate that in presence of an sEH inhibitor, stabilization of EET levels 353 
results in enhanced local utilization reducing concentrations of VEGF, although long 354 
term studies are necessary to fully assess the potential effects. 355 
More recent studies have suggested that under conditions of low VEGF signaling, 356 
EETs may increase the response to VEGF [23,24], thus, offering a novel therapeutic 357 
approach to target endothelial apoptosis and subsequent tissue loss, as has been 358 
demonstrated in emphysema [37–41].  Our results demonstrate that sEH inhibition 359 
with GSK2256294 is well tolerated, with rapid and sustained target inhibition. The 360 
results from these studies provide a meaningful rationale for future studies with 361 
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GSK2256294, particularly in diseases characterized by endothelial dysfunction or 362 
abnormal tissue repair, such as diabetes, wound healing or emphysema. 363 
  364 
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Figure Legends 392 
Figure 1: Subject Disposition, Study 1 393 
 394 
 395 
Figure 2: Single and Repeat Dose Pharmacokinetics of GSK2256294.  396 
Concentration-time plots following single (A) and repeat (B) doses of GSK2256294.  397 
Data are expressed as mean ±SD.  HV-healthy volunteer; OS-overweight smoker 398 
 399 
 400 
Figure 3: Dose-dependent inhibition of sEH enzyme activity.  Percent inhibition 401 
of sEH enzyme activity following single (A) and repeat (B) dosing with GSK2256294.  402 
Data are expressed as mean ±SD.  HV-healthy volunteer; OS-overweight smoker 403 
 404 
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Abstract 
Aims: Endothelial-derived epoxyeicosatrienoic acids may regulate vascular toneand 
are metabolised by soluble epoxide hydrolase enzymes (sEH). GSK2256294 is a 
potent and selective sEH inhibitor that was tested in two Phase I studies.  
Methods: Single escalating doses of GSK2256294 2-20 mg or placebo were 
administered in a randomized crossover design to healthy male subjects or obese 
smokers; once daily doses of 6 or 18 mg or placebo were also administered for 14 
days to obese smokers.  Data were collected on safety, pharmacokinetics, sEH 
enzyme inhibition and blood biomarkers. Single doses of GSK2256294 10 mg were 
also administered to healthy younger males or healthy elderly males and females 
with and without food.  Data on safety, pharmacokinetics and biliary metabolites were 
collected.  
Results: GSK2256294 was well-tolerated with no serious adverse events (AEs) 
attributable to the drug. The most frequent AEs were headache and contact 
dermatitis.  Plasma concentrations of GSK2256294 increased with single doses, with 
a half-life averaging 25-43 hours. There was no significant effect of age, food or 
gender on pharmacokinetic parameters. Inhibition of sEH enzyme activity was dose-
dependent, from an average of 41.9% on 2 mg (95% confidence interval [CI] -51.8, 
77.7) to 99.8% on 20 mg (95% CI 99.3, 100.0) and sustained for up to 24 hours.  
There were no significant changes in serum VEGF or plasma fibrinogen.  
Conclusions: GSK2256294 was well-tolerated and demonstrated sustained 
inhibition of sEH enzyme activity.  These data support further investigation in patients 
with endothelial dysfunction or abnormal tissue repair, such as diabetes, wound 
healing or COPD.   
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What is known about this subject? 
• Soluble epoxide hydrolase (sEH) is a critical enzyme in the metabolism of 
epoxyeicosatrienoic acids (EETs). 
 
• EETs released from the endothelium exhibit anti-inflammatory effects, 
regulate vascular tone and may have a cytoprotective role 
 
• GSK2256294 is a potent and selective, orally-available sEH inhibitor 
 
What this study adds  
GSK2256294 is a well-tolerated and highly effective oral sEH inhibitor irrespective of 
age, gender or food administration.   
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Introduction 
Epoxyeicosatrienoic acids (EETs) are one of many vasoactive factors released by 
the vascular endothelium, including nitric oxide (NO), prostacyclin, and endothelium 
derived hyperpolarizing factors. EETs are formed by the oxidation of arachidonic acid 
by cytochrome P450 enzymes. Soluble epoxide hydrolase (sEH, an EPHX2 gene 
product) is a critical enzyme in the metabolism of EETs to their corresponding much 
less active or less available dihydroxyeicosatrienoic acids (DHETs) [1,2].  In addition, 
EPHX2 contains a phosphatase domain of unknown function.  EETs have 
demonstrated a wide range of activities including protection of endothelial cell 
survival and function in both coronary and pulmonary derived cells, as well as anti-
inflammatory and pro-resolving functions and protection of organs from damage [3–
5]. The mechanism of action of EETs is complex, and may include changes in 
potassium channel open states, as well as engagement of as yet unidentified 
receptors or action through peroxisome proliferator-activated receptors [3]. 
Preclinical data with sEH inhibitors provide evidence for a number of potentially 
beneficial cardioprotective effects [6–10].  Exogenous EETs and sEH inhibitors are 
also efficacious in a wide variety of animal models of pulmonary disease such as 
smoke-induced airway inflammation and airspace enlargement, allergen-induced 
airway inflammation, bleomycin-induced pulmonary fibrosis and toxin-induced lung 
injury [11–16].  High levels of sEH activity inversely correlate with low concentrations 
of the pro-resolving lipoxin A4 in sputum supernatants of patients with severe asthma 
[17].  It is proposed that the inhibition of sEH will increase the cellular concentration 
of EETs and thus increase their positive cellular effects.   
Clinical studies with sEH inhibitors are limited.  The selective sEH inhibitor AR9281 
(Arete Pharmaceuticals) was shown to improve endothelial function in animal models 
[18] and demonstrated inhibition of enzyme activity and a modest decrease in 
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dihydroxy lipids in a clinical study in healthy subjects [19]. A Phase 2 trial to assess 
effects on blood pressure and glucose metabolism in patients with moderate 
hypertension and impaired glucose tolerance was terminated (NCT00847899). 
GSK2256294 is a potent, tight-binding but reversible inhibitor of sEH.  It is specific for 
the hydrolase domain of EPHX2 and is inactive against the phosphatase domain and 
has been shown to attenuate cigarette smoke-induced lung inflammation in animal 
models [20]. We report data from two clinical trials designed to test the safety, 
pharmacokinetics, and pharmacodynamics of GSK2256294 in healthy subjects.  
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Methods 
Clinical Study design  
Study 1, First-time-in-human (FTIH, GSK protocol SEH114068, ClinicalTrials.gov 
identifier NCT01762774). The FTIH study was a single-center, randomized, double-
blind, placebo-controlled design comprising four cohorts.  Study 1 recruited healthy 
male non-smokers between 18-65 years of age with body mass index (BMI) 19-
25kg/m2 for Cohort 1, and moderately overweight smokers (defined as ≥10 
cigarettes/day for at least 1 year prior to the screening visit) with BMI 26 – 35kg/m2 
for Cohorts 2-4. Subjects with abnormal liver function, who were on statins, or who 
had hypertension or other significant cardiac, pulmonary, metabolic, renal, or 
gastrointestinal conditions, were excluded.  
Single escalating doses of GSK2256294 (2, 6, 10, 12, and 20mg) or placebo were 
administered in a randomised crossover design to Cohorts 1 and 2. Single dosing 
subjects followed a 4-period dosing schedule with placebo insertion, such that all 
subjects received placebo and three doses of the active drug randomly over the 
course of the study. Subjects were assigned to the treatment regimens in 
accordance with a randomisation schedule that included 4 sequences with 3 subjects 
assigned to each sequence. 
The emerging pharmacokinetic (PK) and pharmacodynamic (PD) data from Cohorts 
1 and 2 were modelled with a population exposure-response analysis approach to 
select appropriate doses for repeat dosing cohorts. Two cohorts of overweight 
smokers were subsequently recruited for repeat dosing, with one cohort randomised 
to receive either 6mg or placebo (Cohort 3), and another 18 mg or placebo (Cohort 
4). Fifteen subjects were planned for each cohort with 12 randomised to the active 
arm and 3 to placebo.  Data were collected on safety, PK, sEH enzyme inhibition and 
blood biomarkers. An experimental medicine study in Cohorts 3 and 4, to provide 
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early proof of mechanism of the potential biological effects of sEH inhibition on 
endothelial function using measurements of forearm blood flow, was also included, 
but reported separately [21]. The trial received favourable ethical opinion from the 
London Bloomsbury Ethics Committee (12/LO/1832) as well as regulatory approval 
by the MHRA.   
Study 2, Food effect (GSK protocol SEH117023, ClinicalTrials.gov identifier 
NCT02006537). The food effect study was open label and performed at a single 
center.  Subjects included healthy males between 18-45 years of age recruited for 
Cohort 1, and healthy male and females (of non-child bearing potential) aged ≥60 
years of age recruited for Cohort 2. 
Subjects in Cohort 1 received a single dose of GSK2256294 10mg, and underwent 
non-invasive bile sampling with the Entero-Test® device, as previously described 
[22].  Subjects in Cohort 2 were randomized to receive two single doses of 
GSK2256294 10 mg in both the fed and fasted state. This trial was reviewed and 
approved by the Aspire Institutional Review Board (Santee, CA, USA). 
Both studies complied with the Declaration of Helsinki 2008 and ICH Good Clinical 
Practice guidelines, and full written informed consent was obtained from all 
participants before the performance of any study-specific procedures. A complete list 
of inclusion and exclusion criteria is available on clinicaltrials.gov. 
Safety 
Safety assessments were monitored using adverse event (AE) reporting, clinical 
laboratory tests, vital signs, ECGs, and physical examinations. In the single dose 
escalation phase of Study 1, 25-hour continuous Holter and electrocardiographic 
monitoring were performed from 1hr pre-dose to 24 hours post-dose.  
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The addition of EETs and/or inhibition of sEH have been linked in preclinical studies 
to two important activities that pose potential clinical risks.  The first set of studies 
concerns the role of EETs and sEH in VEGF signaling and expression [23,24]; for 
this reason, we measured VEGF concentrations in the repeat dose cohorts of Study 
1 (described below).  The second set of studies concerns control of acute pulmonary 
vasoconstriction and pulmonary hypertension.  Mice in which the sEH gene has been 
deleted develop pulmonary hypertension in response to chronic hypoxia, but sEH 
inhibition in wild-type mice does not recapitulate the knockout [25].  At this time, a 
role of the EPHX2 gene in development of pulmonary hypertension is focused on the 
phosphatase domain, which is unaffected by GSK2256294 [20]; nevertheless, we 
measured pulmonary artery pressure using transthoracic echocardiography in the 
repeat dose cohorts of Study 1.  
Measurement of GSK2256294 
GSK2256294 was extracted from 50 µL of human plasma by protein precipitation 
using acetonitrile containing an isotopically labelled internal standard ([2H3
13C]-
GSK2256294) and extracts were analysed for GSK2256294 by HPLC-MS/MS using 
a TurboIonSpray™ interface and multiple reaction monitoring. The assay was 
validated over the range 0.6 to 250 ng/mL of GSK2256294, with calibration 
correlation coefficients of >0.996, obtained using 1/(x2) weig ted linear regression. 
The assay precision (%CV) was ≤12.9% for within-run and ≤4.7% between-runs, with 
an accuracy (%bias) between -9.5%≤ bias ≤14.5%. 
Soluble Epoxide Hydrolase Activity Assay 
Blood samples were collected from subjects in Cohorts 1-4 (Study 1), immediately 
mixed by inversion in NaF/Potassium oxalate containing tubes and stored at 2-8°C 
for up to 12 hours (if not processed immediately). Whole blood samples were 
assessed for both sEH activity and non-sEH mediated EET hydrolysis, by pre-
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incubating for 20 minutes at room temperature with either 25 mM HEPES/10 µM 
CHAPS buffer (pH 7-7.6) either alone or with addition of a known potent sEH inhibitor 
(final concentration 10uM GSK2188931), respectively. The reactions were initiated 
by the addition of 14,15-EET-deuterated (d11) substrate in HEPES/CHAPS buffer 
(0.45 µM final concentration) and incubated for 30 minutes at room temperature. The 
enzymatic reaction was terminated by the addition of zinc sulfate (3.3 mM final 
concentration) and subsequently diluted with an equal volume of distilled water 
(~300uL) prior to storage at ca. -70°C. Samples were analysed for the conversion of 
14,15-EET-d11 to 14,15-DHET-d11 by LC/MS/MS, using an assay that was validated 
over the range 0.5 to 500 ng/mL for 14,15-EET-d11 and 0.1 to 100 ng/mL for 14,15-
DHET-d11, with calibration correlation coefficients obtained using 1/(x2) weighted 
linear regression of >0.996 and 0.997, respectively. The assay precision (%CV) was 
≤17.5% (14,15-EET-d11) and ≤13.3% (14,15-DHET-d11) for within-run and ≤4.6% 
(14,15-EET-d11) and ≤13.7% (14,15-DHET-d11) between-runs, with an accuracy 
(%bias) between -9.2% ≤ bias ≤5.7% (14, 15 EET) and -5.5% ≤ bias ≤22.9% (14, 15 
DHET).  The sEH activity was evaluated by the formation of 14,15-DHET-d11, 
corrected for non-sEH mediated hydrolysis and subsequently the % inhibition of sEH 
activity following GSK2256294 dose escalation was defined. 
Blood biomarkers 
VEGF was measured using a validated ELISA (performed by Quest Diagnostics, 
Valencia, CA). Plasma fibrinogen was measured using the modified Clauss method.  
Detailed methods for the analysis of Leukotoxin/Leukotoxin-diol (LT/LTD) assays are 
included in the Supplemental material [26].  
Analysis and Statistical methods 
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These studies focused primarily on the safety, tolerability, and pharmacokinetics (PK) 
of GSK2256294, and no formal hypotheses around the pharmacodynamic 
assessments were tested. 
Plasma concentration-time data were analysed by non-compartmental methods with 
WinNonlin 6.3 and calculations were based on the actual sampling times recorded 
during the study.  Actual elapsed times from dosing were used to estimate all 
individual plasma PK parameters for evaluable subjects. Based on available data, 
various PK parameters were estimated following GSK2256294 dose administration in 
single dose and repeat dose, including maximum observed plasma concentration 
(Cmax), time to Cmax (tmax), the apparent terminal elimination half-life (t1/2), and 
the area under the plasma concentration-time curve (AUC). Descriptive statistics (n, 
arithmetic mean, standard deviation, 90% CI, minimum, median and maximum) were 
calculated for all PK parameters by treatment. Dose proportionality was assessed by 
using Power model and Analysis of Variance.  
A preliminary interim analysis of the systemic concentrations of GSK2256294 
(exposure) and the sEH enzyme inhibition (response) data was conducted to select a 
starting dose for the repeat dose arm using a population modeling and simulation 
approach. 
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Results 
Safety 
Fifty-six male subjects aged 18-65 years inclusive were recruited to take part in 
Study 1. Fourteen healthy male non-smokers were recruited into cohort 1, and 42 
moderately overweight smokers were recruited into cohorts 2 - 4. Forty-eight 
subjects completed the study as planned. Detailed subject disposition is shown in 
Figure 1.  In study 2, 8 subjects were randomized into Cohort 1 and 18 subjects were 
randomized into Cohort 2.  All subjects completed the study. Demographics for both 
studies are shown in Table S1 of the online supplement.  
Overall, GSK2256294 was well-tolerated with no serious adverse reactions attributed 
to the drug. One serious adverse event of nephrolithiasis occurred in a subject who 
received a single dose of 2 mg in Study 1; this subject had a previous history of 
nephrolithiasis and the event was not considered to be drug-related, although the 
subject was withdrawn from the study. One additional subject was withdrawn after a 
vasovagal episode while a blood sample was being obtained, which was not felt to 
be drug-related. No subjects were withdrawn for adverse events in the repeat dose 
cohorts. 
The most frequent adverse events in study 1 were headache and contact dermatitis 
in the healthy subjects (Cohort 1), and headache and nasopharyngitis in the obese 
smokers (cohorts 2-4)(Supplemental Tables S2-S4). The occurrence of AEs was 
similar between the active and placebo groups, with the exception of contact 
dermatitis at the site of ECG electrode placement, which occurred in 9 healthy 
subjects receiving the active drug, and none in the placebo group. The majority of 
AEs were mild-moderate in severity.  In the single dose cohorts, five subjects were 
noted to have a transient elevation of creatinine at the 12 hour time point after dosing 
(1 on placebo, 2 each on GSK2256294 2mg or 6 mg).  Contemporaneous Cystatin C 
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concentrations in these subjects were normal (data not shown) and creatinine 
concentrations were within the normal range at the 24 hour time point.  No changes 
in creatinine were noted in the repeat dose cohorts.  The subject with nephrolithiasis 
was noted to have increased hepatic transaminases at the time of his hospitalization.  
One additional subject had a transient increase in alanine aminotransferase noted 
after a single dose of 10 mg GSK2256294; no clinically significant changes in 
transaminases were seen in the repeat dose cohorts. Finally, there were no changes 
in the pulmonary artery pressures of subjects who received 14 days repeat dosing of 
GSK2256294 in Study 1. 
There were 3 AEs in study 2 and none was reported in more than one person (Table 
S5). No clinically significant differences in ECG or vital signs were noted in either 
study.   
Pharmacokinetics and Metabolism 
GSK256294 was well absorbed with maximum systemic concentrations achieved 
around 1-2 hours and with a dose proportional increase in systemic exposure from 6 
mg to 20 mg. The observed half-life was 20-30 hours (Figure 2A).  The exposure and 
t½ were slightly higher in obese smokers as compared to healthy volunteers (Table 
1). With once daily repeat dosing, steady state was achieved within 6-8 days and 
resulted in approximately 2 fold accumulation (Figure 2B).   
The preliminary exposure data and enzyme inhibition data from the single dose 
cohorts in FTIH were utilized to characterize the sEH enzyme inhibition and 
determine an approximate clinical dose for the repeat dose cohorts.  An indirect 
response model was built to characterize the sustained enzyme inhibition following 
single dose administration. A population kinetic-pharmacodynamic model (KPD) 
model adequately characterized the observed sEH enzyme inhibition at different 
dose levels. The doses rather than systemic drug concentrations provided a better fit 
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of the observed data and this the KPD approach was used [27]. Simulations were 
performed with the KPD model to predict the probability of 90% or higher level of 
enzyme inhibition after 2 weeks of once daily dosing at different dose levels. The 6 
mg dose presented a very high probability of achieving >90% sEH enzyme inhibition 
at once daily dosing for 2 weeks.  Assuming a less than 2 fold accumulation, the 18 
mg dose was then selected to help characterize the safety and tolerability of a high 
dose of GSK2256294, while maintaining exposures within the stopping criteria based 
on animal safety studies. 
Data from Study 2 demonstrated no impact on systemic exposure of GSK2256294 
due to age or gender. There was an approximately 22% increase 1.22 (90% CI 1.10, 
1.34) in AUC when GSK2256294 was administered with FDA recommended meal as 
compared to fasted state with no change in the Cmax. This increase in exposure 
when GSK2256294 is administered with food is clinically insignificant. 
 
In Study 2, GSK2256294 and five metabolites were detected in the pooled human 
duodenal bile samples by mass spectroscopy.  Unchanged parent was the major 
drug-related component, with metabolites being formed by oxidation with or without 
subsequent glucuronidation (data not shown). 
 
sEH Enzyme inhibition  
.  Following single doses of GSK2256294, there was a dose-dependent inhibition 
from an average of 41.9% on 2 mg (95% CI -51.8, 77.7) to an average of 99.8% on 
20 mg (95% CI 99.3, 100.0)(Figure 3A).  The duration of inhibition was sustained for 
up to 24 hours. Near maximal inhibition of sEH enzyme activity (98-99%) was 
observed for both 6mg and 18 mg following 14 days repeated dosing (Figure 3B). 
Repeat dose enzyme inhibition at 6 mg/day and 18 mg/day (Cohorts 3 and 4, 
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respectively) was consistent with the single dose inhibition at 6 hr (98-99 %) at both 
doses, and this was maintained at 24h after repeat dosing. 
A large number of the endogenous LT levels were non-quantifiable, as they were 
below the limit of LC/MS/MS assay detection (LLQs of 250 pg/mL and 50 pg/mL for 
LT and LTD, respectively). In addition, there were no meaningful changes in the 
LT/LTD ratio between any of the three treatment arms compared to baseline at any 
time point (data not shown).  
Blood biomarkers 
In the repeat dosing subjects in Study 1, there were no significant changes in VEGF 
concentrations from baseline to day 15. The fold change from baseline in the placebo 
group was 1.06 (95% CI: 0.73, 1.55), and 1.15 (95% CI: 0.85, 1.56), in the 6mg 
group.  There was a trend for a decrease in VEGF in subjects receiving 18mg of 
GSK2256294 (ratio to baseline 0.77 (95% CI: 0.56, 1.05)). 
Adjusted mean values of plasma fibrinogen were within the normal range and were 
similar across all groups.  The average difference at day 15 compared with placebo 
was negligible.  The fold change from baseline in subjects who received 6mg 
GSK2256294 was 1.06 (95% CI: 0.82, 1.37), and 1.04 (95% CI: 0.81, 1.34) in those 
who received 18mg GSK2256294.  
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Discussion 
We report the first studies to assess the safety, pharmacokinetics and 
pharmacodynamic effects of the sEH inhibitor GSK2256294, in healthy subjects and 
otherwise healthy overweight smokers.  Overweight smokers represent a population 
with endothelial dysfunction manifested by reduced NO-mediated vasodilatation and 
impaired fibrinolytic pathways; in this situation, up-regulation of EETs would be 
expected to play a compensatory role.  Preclinical studies of sEH inhibition in models 
of metabolic syndrome support obesity as a factor regulating this pathway [8,28]. 
Finally, smoking has a synergistic effect with sEH polymorphisms coding for 
enhanced sEH enzyme [29], though subjects were not genotyped in this study. 
GSK2256294 was rapidly absorbed and demonstrated an approximately dose 
proportional increase in exposure from 6 mg to 20 mg dose with a half life consistent 
with once daily dosing.  The majority of GSK2256294 was cleared within 72 hrs of 
dosing, yet very low concentrations of parent compound were detectable in the 
plasma for up to 3 weeks.  While the mechanism for this is unknown, one potential 
explanation may be that a small amount of GSK2256294 is distributed to a deep 
compartment and was then eliminated slowly. 
GSK2256294 was well tolerated following both single and repeat dosing, and the 
majority of adverse events were classified as mild to moderate. Transient elevations 
of creatinine were noted in the single dose cohorts of the FTIH study that were 
considered possibly drug-related, and occurred primarily in subjects receiving 
GSK2256294. These events were only noted at a single time point, occurred soon 
after a meal and only at 2 and 6 mg but not higher doses, and did not re-occur with 
subsequent dosing, nor were they associated with elevations in serum cystatin C or 
urinalysis abnormalities. No changes in creatinine were observed in the repeat dose 
cohorts. The etiology of these transient changes is unknown. One possibility which 
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may explain why this was only seen at lower doses, and not in repeat dosing, is the 
fact that the 12 hour blood sampling point was only done in Cohorts 1 and 2, i.e. 
immediately after the evening meal, and that the changes in creatinine were related 
to dietary intake (a heavy protein meal eaten immediately prior to sampling) as 
previously reported in the literature [30], although a formal dietary chart was not kept 
for the trial. 
In pre-clinical models, EETs increase the proliferation and survival of endothelial 
cells [31] as well as induce angiogenesis [32,33].  The critical role for EETs in organ 
regeneration and tissue repair may be dependent on this effect [34].  Using the same 
experimental model, investigators also demonstrated that transgenic overexpression 
of EETs or inhibition of sEH promoted tumor growth and metastasis [35]. In contrast, 
dual inhibition of cyclo-oxygenase 2 and soluble epoxide hydrolase has 
demonstrated synergistic anti-angiogenic and anti-cancer activity [36].  The 
relevance of these models to humans is unknown, but suggests that the regulation of 
sEH activity and tissue EETs in tumor growth is complex.  In the FTIH study, serum 
VEGF concentrations were not increased following 2 weeks of dosing with 
GSK2256294, and actually trended lower in subjects who received the higher dose.  
One might speculate that in presence of an sEH inhibitor, stabilization of EET levels 
results in enhanced local utilization reducing concentrations of VEGF, although long 
term studies are necessary to fully assess the potential effects. 
More recent studies have suggested that under conditions of low VEGF signaling, 
EETs may increase the response to VEGF [23,24], thus, offering a novel therapeutic 
approach to target endothelial apoptosis and subsequent tissue loss, as has been 
demonstrated in emphysema [37–41].  Our results demonstrate that sEH inhibition 
with GSK2256294 is well tolerated, with rapid and sustained target inhibition. The 
results from these studies provide a meaningful rationale for future studies with 
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GSK2256294, particularly in diseases characterized by endothelial dysfunction or 
abnormal tissue repair, such as diabetes, wound healing or emphysema. 
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Figure Legends 
Figure 1: Subject Disposition, Study 1 
 
 
Figure 2: Single and Repeat Dose Pharmacokinetics of GSK2256294.  
Concentration-time plots following single (A) and repeat (B) doses of GSK2256294.  
Data are expressed as mean ±SD.  HV-healthy volunteer; OS-overweight smoker 
 
 
Figure 3: Dose-dependent inhibition of sEH enzyme activity.  Percent inhibition 
of sEH enzyme activity following single (A) and repeat (B) dosing with GSK2256294.  
Data are expressed as mean ±SD.  HV-healthy volunteer; OS-overweight smoker 
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Table 1: Selected Plasma GSK2256294 Pharmacokinetic Parameters 
Treatment Cmax 
(ng/mL) 
AUC(0-24) 
(ng.h/mL]) 
AUC(0-∞) 
(ng.h/mL) 
t1/2 
(h) 
tmax 
(h) 
Cohort 1 (SD) 
2mg 29.6 (79.6) 111 (124) 1272 (17.9) 29.9 (11.8) 0.50 (0.3-1.0) 
6mg 321 (44.7) 2471 (37.3) 3376 (37.3) 25.0 (23.6) 1.00 (0.5-4.0) 
12mg 836 (33.4) 6680 (23.4) 8641 (26.8) 19.3 (11.0) 0.63 (0.5-1.0) 
Cohort 2 (SD) 
6mg 333 (29.4) 3244 (18.4) 5905 (24.7) 48.8 (36.3) 1.00 (0.5-3.0) 
10mg 559 (32.8) 5267 (34.6) 9611 (46.9) 42.7 (52.7) 1.00 (0.5-2.0) 
20mg 1223 (23.2) 11464 (31.0) 17359 (35.8) 41.4 (35.7) 1.00 (0.5-4.0) 
Cohort 3-4 (RD) 
6mg 689 (33.2) 5801 (57.5) ND ND 0.52 (0.5-1.0) 
18mg 1455 (29.1) 15774 (36.3) ND ND 0.50 (0.5-2.0) 
 
Selected pharmacokinetic parameters from the FTIH study (Study 1), expressed as geometric 
mean (coefficient of variance [CV]%), with the exception of tmax, which is expressed as median 
(range).  ND-not determined; SD-single dose; RD-14 day repeat dose 
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Figure 1  
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Figure 2: Single and Repeat Dose Pharmacokinetics of GSK2256294.  Concentration-time plots following 
single (A) and repeat (B) doses of GSK2256294.  Data are expressed as mean ±SD.  HV-healthy volunteer; 
OS-overweight smoker  
222x105mm (96 x 96 DPI)  
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Figure 3: Dose-dependent inhibition of sEH enzyme activity.  Percent inhibition of sEH enzyme activity 
following single (A) and repeat (B) dosing with GSK2256294.  Data are expressed as mean ±SD.  HV-healthy 
volunteer; OS-overweight smoker  
222x100mm (96 x 96 DPI)  
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Supplemental Data 
 
Leukotoxin/Leukotoxin-diol (LT/LTD) Assays 
Blood samples were collected from subjects in Cohorts 3-4, into EDTA containing tubes, placed 
on crushed ice prior to centrifugation to obtain plasma (ca. 1500 x g for 15 minutes, 4°C) and 
stored at -20°C or colder (within 1h of blood collection). Samples were analysed for the 
determination of endogenous levels of LT converted to LTD by LC/MS/MS, with assay LLQs of 
250 pg/mL and 50 pg/mL, respectively. 
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Table S1: Demography 
 
Study 1 
 
Demographics Single Dose  Repeat Dose 
 Cohort 1 
(n=14) 
Cohort 2 
(n=13) 
GSK2256294 6 
mg (n=11) 
GSK2256294 
18 mg (n=12) 
Placebo 
(n=6) 
Age in Years Mean (SD) 32.4 (7.92) 38.9 (9.57) 42.9 (10.48) 42.4 (9.46) 41.3 (8.04) 
Sex [n (%)]      
Male: 14 (100) 13 (100) 11 (100) 12 (100) 6 (100) 
BMI (kg/m2) Mean (SD) 23.15 
(1.446) 
30.26 
(1.640) 
30.55 (1.675) 30.92 (2.265) 30.55 
(2.894) 
Height (cm) Mean (SD) 178 (5.0) 181 (4.7) 183 (6.0) 178 (4.3) 176 (9.0) 
Weight (kg) Mean (SD) 73.2 (6.57) 98.9 (8.80) 102.8 (9.90) 98.3 (10.14) 94.5 (9.24) 
Ethnicity n (%)      
Not Hispanic or Latino: 14 (100) 13 (100) 11 (100) 12 (100) 6 (100) 
Race n (%)      
Asian – South East Asian Heritage 0 1 (8) 1(9) 1 (8) 0 
Black or African American 1 (7) 0 0 2 (17) 0 
White – White/Caucasian/European 
Heritage 
13 (93) 12 (92) 10 (91) 9 (75) 6 (100) 
 
 
Study 2 
 
Demographics Cohort 1 
(N=8) 
Cohort 2 
(N=18) 
Age in Years [Median (Range)] 36 (20-40) 62 (59-75) 
Sex [n (%)]   
Female: 0 8 (44) 
Male: 8 (100) 10 (56) 
BMI (kg/m2) [Median (Range)] 24.50 (20.40-28.80) 27.85 (21.50-33.00) 
Height (m) [Median (Range)] 1.77 (1.66-1.90) 1.73 (1.58-1.91) 
Weight (kg) [Median (Range)] 79.3 (61.2-100.0) 79.3 (64.2-113.0) 
Ethnicity [n (%)]   
Hispanic or Latino: 2 (25) 1 (6) 
Not Hispanic or Latino: 6 (75) 17 (94) 
Race [n (%)]   
African American/African Heritage 5 (63) 11 (61) 
Asian – South East Asian Heritage 0 1 (6) 
White –  White/Caucasian/European Heritage 3 (38) 6 (33) 
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Supplemental Table 2: Adverse Events reported in Cohort 1, study 1 
System organ class 
preferred term, n (%) 
Placebo 
(n=12) 
GSK2256294 
2 mg  
(n=12) 
GSK2256294 
6 mg 
(n=12) 
GSK2256294 
12 mg  
(n=12) 
Subjects with Any 
Adverse Event 
4 (33) 9 (75) 8 (67) 6 (50) 
Skin and subcutaneous 
tissue disorders  
    
Dermatitis contact 0 4 (33) 3 (25) 1 (8) 
Nervous system 
disorders  
    
Headache 2 (17) 1 (8) 2 (17) 3 (25) 
General disorders and 
administration site 
conditions  
    
Catheter site erythema 0 0 0 2 (17) 
Investigations      
Blood creatinine increased 0 2 (17) 1 (8) 0 
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Supplemental Table 3: Adverse Events reported in Cohort 2, study 1 
System organ class 
preferred term, n (%) 
Placebo 
(n=12) 
GSK2256294 
2 mg  
(n=12) 
GSK2256294 
6 mg 
(n=12) 
GSK2256294 
12 mg  
(n=12) 
Subjects with Any 
Adverse Event 
7 (64) 7 (64) 8 (80) 6 (75) 
Nervous system 
disorders  
    
Headache 3 (27) 2 (18) 3 (30) 2 (25) 
Somnolence 0 0 0 2 (25) 
Musculoskeletal and 
connective tissue 
disorders 
    
Back pain 0 2 (18) 0 1 (13) 
Gastrointestinal 
disorders 
    
Flatulence 0 1 (9) 2 (20) 0 
General disorders and 
administration site 
conditions 
    
Fatigue 3 (27) 0 1 (10) 0 
Infections and 
infestations  
    
Nasopharyngitis 0 2 (18) 0 0 
Investigations     
Hepatic enzyme increased 0 2 (18) 0 0 
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Supplemental Table 4: Adverse Events reported in Cohorts 3 and 4, Study 1 
 
 
 
 
 
Supplemental Table S5: Adverse events reported in Study 2 
 
System Organ Class 
Preferred Term  
GSK2256294 10 mg 
(N=8) 
GSK2256294 10 mg  
(N=18) 
Subjects with Any Adverse Event 2 (25) 1 (6) 
Gastrointestinal disorders   
Flatulence 0 1 (6) 
General disorders and 
administration site conditions   
Catheter site swelling 1 (13) 0 
Musculoskeletal and connective tissue 
disorders   
Pain in extremity 1 (13) 0 
 
 
System organ class 
preferred term, n (%) 
Placebo  
(n=6) 
GSK2256294 
6 mg (n=11) 
GSK2256294 
18 mg (n=12) 
Subjects with Any 
Adverse Event 
5 (83) 9 (82) 9 (75) 
Nervous system 
disorders  
   
Headache 3 (50) 4 (36) 5 (42) 
Dizziness 0 0 2 (17) 
Musculoskeletal and 
connective tissue 
disorders  
   
Back pain 1 (17) 2 (18) 0 
Neck pain 0 1 (9) 2 (17) 
Gastrointestinal 
disorders  
   
Abdominal pain 0 2 (18) 0 
Infections and 
infestations  
   
Nasopharyngitis 0 3 (27) 2 (17) 
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